Newsroom

EQRx Appoints Carlos Garcia-Echeverria, Ph.D., as Chief of Rx Creation

EQRx and Exscientia announced a strategic research and development collaboration agreement to accelerate the discovery of multiple small molecule therapeutic drug candidates in multiple therapeutic areas, including oncology & immunology, further expanding the breadth of EQRx’s pipeline of novel therapies.

Primary Endpoint Met in Phase 3 Study of the Anti-PD-L1 Antibody Sugemalimab in Stage III Non-Small Cell Lung Cancer

Aumolertinib Significantly Prolongs Progression Free Survival with Fewer Side Effects in the First-Line Treatment of Advanced EGFR-Mutated Non-Small Cell Lung Cancer

EQRx Appoints Jami Rubin as Chief Financial Officer and Kent Rogers as Chief Customer Officer